Item 2.02. Results of Operations and Financial Condition.

The information in this Item 2.02, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), except as expressly set forth by specific reference in such filing.

On March 4, 2020, AMAG Pharmaceuticals, Inc. ("AMAG") issued a press release announcing its operating results for the quarter and year ended December 31, 2019 and its intention to hold a conference call to discuss AMAG's financial results and provide a business update, including an update on recent corporate developments. A copy of AMAG's press release is furnished herewith as Exhibit 99.1 and a copy of the presentation slides to be used during the conference call is furnished herewith as Exhibit 99.2.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 4, 2020, AMAG also announced that Julie Krop, M.D., AMAG's Executive Vice President and Chief Medical Officer, will be leaving AMAG, effective March 31, 2020. In exchange for her agreeing to provide support and transition services through March 31, 2020, AMAG has agreed to provide Dr. Krop with a lump-sum payment of $288,000, subject to certain conditions, including that Dr. Krop execute an effective release and waiver of claims for the benefit of AMAG, as provided in a separation letter expected to be entered into on or about the date hereof.

The foregoing description of the separation letter is not complete and is qualified in its entirety by reference to the letter, which will be filed as an exhibit to AMAG's Quarterly Report on Form 10-Q for the quarter ending March 31, 2020.

Item 7.01. Regulation FD Disclosure.

The information in this Item 7.01, including Exhibit 99.3 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing.

On March 4, 2020, AMAG issued a press release announcing Dr. Krop's departure and related matters. A copy of AMAG's press release is furnished herewith as Exhibit 99.3.

Item 9.01. Financial Statement and Exhibits.





(d) Exhibits.



Exhibit
No.                                      Description
             Press Release of AMAG Pharmaceuticals, Inc., dated March 4, 2020
  99.1     (furnished herewith)
             Copy of AMAG Pharmaceuticals, Inc.'s presentation slides dated March
  99.2     4, 2020 (furnished herewith)
             Press Release of AMAG Pharmaceuticals, Inc., dated March 4, 2020
  99.3     (furnished herewith)




                                       2

© Edgar Online, source Glimpses